Articles related to ALZHEIMER'S/DEMENTIA

The recent study underscores the limited eligibility for new monoclonal antibody treatments in early Alzheimer’s patients, emphasizing the need for more inclusive research. Explore the detailed findings to understand the implications for treatment availability in diverse populations.

Join this essential Expert Exchange webcast on Identifying and Assessing Agitation in Alzheimer’s Dementia. With a duration of just 30 minutes and offering 0.50 credits, this program provides a unique opportunity to enhance your clinical skills and understanding of this critical aspect of Alzheimer’s care.

Explore the recent meta-analysis that delves into the potential of cholinesterase inhibitors in treating delusions and hallucinations in dementia patients. The findings reveal significant but clinically insignificant effects, highlighting the need for further research and targeted treatments.

The landscape of Alzheimer’s treatment is evolving with the introduction of antiamyloid monoclonal antibodies. Here is some clinical guidance to stay at the forefront of patient care.

Results from the TRAILBLAZER-ALZ 2 trial highlight the efficacy of donanemab in slowing the progression of early symptomatic Alzheimer disease over a period of 76 weeks.

A phase 3 clinical trial of solanezumab, an antibody that targets monomeric amyloid, showed no significant slowing of cognitive decline in patients with preclinical Alzheimer’s disease over 240 weeks, despite decreased brain amyloid levels.